Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Current Deferred Revenue (2017)

UroGen Pharma (URGN) has disclosed Current Deferred Revenue for 1 consecutive years, with $650000.0 as the latest value for Q4 2017.

  • For the quarter ending Q4 2017, Current Deferred Revenue changed N/A year-over-year to $650000.0, compared with a TTM value of $650000.0 through Dec 2017, changed N/A, and an annual FY2017 reading of $650000.0, changed N/A over the prior year.
  • Current Deferred Revenue was $650000.0 for Q4 2017 at UroGen Pharma.
  • Across five years, Current Deferred Revenue topped out at $650000.0 in Q4 2017 and bottomed at $650000.0 in Q4 2017.